Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V-DIFFERENCE
NCT05192941Phase 4Completed
- Sponsor
- Novartis
- Start
- Apr 2022
- Primary completion
- Jun 2024
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 8
01
Overview
A Phase 4 trial of inclisiran in hypercholesterolemia, sponsored by Novartis. Started Apr 2022; status: completed.
02
Drugs
inclisiran
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT05192941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05192941.